Table 1

Patient demographics and baseline characteristics (randomised set)

VonoprazanLansoprazoleTotal
(n=244)(n=237)(n=481)
Country/area, n (%)
 Mainland China143 (58.6)133 (56.1)276 (57.4)
 South Korea52 (21.3)55 (23.2)107 (22.2)
 Taiwan28 (11.5)25 (10.5)53 (11.0)
 Malaysia21 (8.6)24 (10.1)45 (9.4)
Age*, years, mean (SD)54.1 (13.16)53.8 (12.53)53.9 (12.84)
Male, n (%)176 (72.1)179 (75.5)355 (73.8)
Height, cm, mean (SD)166.1 (8.24)166.3 (8.80)166.2 (8.52)
Weight, kg, mean (SD)68.48 (12.311)70.26 (12.133)69.35 (12.243)
BMI, kg/m2, mean (SD)24.70 (3.389)25.31 (3.430)25.00 (3.419)
Smoking status, n (%)
 Never smoked157 (64.3)137 (57.8)294 (61.1)
 Current smoker48 (19.7)64 (27.0)112 (23.3)
 Ex-smoker39 (16.0)36 (15.2)75 (15.6)
Consumption of alcohol, n (%)
 Every day13 (5.3)12 (5.1)25 (5.2)
 Two days a week32 (13.1)40 (16.9)72 (15.0)
 Two days a month57 (23.4)48 (20.3)105 (21.8)
 Never142 (58.2)137 (57.8)279 (58.0)
Consumption of caffeine†, n (%)
 Yes58 (23.8)52 (21.9)110 (22.9)
 No185 (75.8)185 (78.1)370 (76.9)
LA classification, n (%)
 Grade A76 (31.1)83 (35.0)159 (33.1)
 Grade B92 (37.7)84 (35.4)176 (36.6)
 Grade C58 (23.8)58 (24.5)116 (24.1)
 Grade D18 (7.4)10 (4.2)28 (5.8)
  • *At the date of informed consent.

  • †One patient with unknown status in the vonoprazan group.

  • BMI, body mass index; LA, Los Angeles.